Modality
Small Molecule
MOA
C5i
Target
Cl18.2
Pathway
T-cell
AML
Development Pipeline
Preclinical
~Oct 2020
→ ~Jan 2022
Phase 1
Apr 2022
→ Sep 2029
Phase 1Current
NCT03610399
1,196 pts·AML
2022-04→2027-09·Active
NCT06400128
2,651 pts·AML
2022-12→2029-09·Active
3,847 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-09-141.5y awayPh2 Data· AML
2029-09-163.5y awayPh2 Data· AML
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Active
P1/2
Active
Catalysts
Ph2 Data
2027-09-14 · 1.5y away
AML
Ph2 Data
2029-09-16 · 3.5y away
AML
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03610399 | Phase 1/2 | AML | Active | 1196 | OS |
| NCT06400128 | Phase 1/2 | AML | Active | 2651 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| PRA-419 | Praxis Precision | Approved | Cl18.2 |